Monday, September 12, 2016 8:04:47 AM
CLSN - 1.20 Pre-market now at 1.32/1.36 so far.
Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer
Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
